The article reports on an agreement of pharmaceutical firm Eli Lilly with Seoul-based company Hanmi Pharmaceutical to develop the latter's Bruton's tyrosine kinase enzyme, citing that Eli Lilly has paid 50 million dollars to Hanmi and mentions that the enzyme in involved in B-cell development.